vs
Apellis Pharmaceuticals, Inc.（APLS）与Bowman Consulting Group Ltd.（BWMN）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是Bowman Consulting Group Ltd.的1.6倍（$199.9M vs $129.0M），Bowman Consulting Group Ltd.净利率更高（1.5% vs -29.5%，领先31.0%），Bowman Consulting Group Ltd.同比增速更快（13.9% vs -5.9%），Bowman Consulting Group Ltd.自由现金流更多（$8.1M vs $-14.3M），过去两年Bowman Consulting Group Ltd.的营收复合增速更高（16.6% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
SLR咨询是一家私有的国际可持续发展咨询企业，在欧洲、北美洲、南美洲、大洋洲及非洲均设有办事处。公司以「推动可持续发展落地」为宗旨，凭借遍布全球的专业顾问与技术团队，携手客户共同应对全球最复杂的各类可持续发展挑战。
APLS vs BWMN — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $129.0M |
| 净利润 | $-59.0M | $2.0M |
| 毛利率 | — | 55.0% |
| 营业利润率 | -25.6% | 3.2% |
| 净利率 | -29.5% | 1.5% |
| 营收同比 | -5.9% | 13.9% |
| 净利润同比 | -62.2% | -66.7% |
| 每股收益（稀释后） | $-0.40 | $0.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $199.9M | $129.0M | ||
| Q3 25 | $458.6M | $126.0M | ||
| Q2 25 | $178.5M | $122.1M | ||
| Q1 25 | $166.8M | $112.9M | ||
| Q4 24 | $212.5M | $113.2M | ||
| Q3 24 | $196.8M | $113.9M | ||
| Q2 24 | $199.7M | $104.5M | ||
| Q1 24 | $172.3M | $94.9M |
| Q4 25 | $-59.0M | $2.0M | ||
| Q3 25 | $215.7M | $6.6M | ||
| Q2 25 | $-42.2M | $6.0M | ||
| Q1 25 | $-92.2M | $-1.7M | ||
| Q4 24 | $-36.4M | $5.9M | ||
| Q3 24 | $-57.4M | $771.0K | ||
| Q2 24 | $-37.7M | $-2.1M | ||
| Q1 24 | $-66.4M | $-1.6M |
| Q4 25 | — | 55.0% | ||
| Q3 25 | — | 53.1% | ||
| Q2 25 | — | 53.7% | ||
| Q1 25 | — | 51.4% | ||
| Q4 24 | — | 53.2% | ||
| Q3 24 | — | 52.4% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 50.6% |
| Q4 25 | -25.6% | 3.2% | ||
| Q3 25 | 48.7% | 4.2% | ||
| Q2 25 | -18.6% | 7.4% | ||
| Q1 25 | -50.0% | 1.0% | ||
| Q4 24 | -12.3% | 1.2% | ||
| Q3 24 | -24.0% | 0.4% | ||
| Q2 24 | -14.7% | -1.2% | ||
| Q1 24 | -36.0% | -2.8% |
| Q4 25 | -29.5% | 1.5% | ||
| Q3 25 | 47.0% | 5.3% | ||
| Q2 25 | -23.6% | 4.9% | ||
| Q1 25 | -55.3% | -1.5% | ||
| Q4 24 | -17.1% | 5.2% | ||
| Q3 24 | -29.2% | 0.7% | ||
| Q2 24 | -18.9% | -2.0% | ||
| Q1 24 | -38.5% | -1.6% |
| Q4 25 | $-0.40 | $0.13 | ||
| Q3 25 | $1.67 | $0.37 | ||
| Q2 25 | $-0.33 | $0.34 | ||
| Q1 25 | $-0.74 | $-0.11 | ||
| Q4 24 | $-0.30 | $0.37 | ||
| Q3 24 | $-0.46 | $0.04 | ||
| Q2 24 | $-0.30 | $-0.13 | ||
| Q1 24 | $-0.54 | $-0.11 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $11.1M |
| 总债务越低越好 | — | $57.6M |
| 股东权益账面价值 | $370.1M | $261.1M |
| 总资产 | $1.1B | $579.7M |
| 负债/权益比越低杠杆越低 | — | 0.22× |
8季度趋势，按日历期对齐
| Q4 25 | $466.2M | $11.1M | ||
| Q3 25 | $479.2M | $16.2M | ||
| Q2 25 | $370.0M | $15.5M | ||
| Q1 25 | $358.4M | $10.7M | ||
| Q4 24 | $411.3M | $6.7M | ||
| Q3 24 | $396.9M | $11.7M | ||
| Q2 24 | $360.1M | $23.1M | ||
| Q1 24 | $325.9M | $11.7M |
| Q4 25 | — | $57.6M | ||
| Q3 25 | — | $29.8M | ||
| Q2 25 | — | $32.0M | ||
| Q1 25 | — | $36.4M | ||
| Q4 24 | — | $38.1M | ||
| Q3 24 | — | $36.4M | ||
| Q2 24 | — | $38.8M | ||
| Q1 24 | $93.1M | $26.8M |
| Q4 25 | $370.1M | $261.1M | ||
| Q3 25 | $401.2M | $261.8M | ||
| Q2 25 | $156.3M | $249.6M | ||
| Q1 25 | $164.2M | $244.1M | ||
| Q4 24 | $228.5M | $246.1M | ||
| Q3 24 | $237.1M | $243.2M | ||
| Q2 24 | $264.3M | $235.6M | ||
| Q1 24 | $266.7M | $167.3M |
| Q4 25 | $1.1B | $579.7M | ||
| Q3 25 | $1.1B | $510.2M | ||
| Q2 25 | $821.4M | $538.2M | ||
| Q1 25 | $807.3M | $528.7M | ||
| Q4 24 | $885.1M | $505.9M | ||
| Q3 24 | $901.9M | $497.0M | ||
| Q2 24 | $904.5M | $463.4M | ||
| Q1 24 | $831.9M | $420.5M |
| Q4 25 | — | 0.22× | ||
| Q3 25 | — | 0.11× | ||
| Q2 25 | — | 0.13× | ||
| Q1 25 | — | 0.15× | ||
| Q4 24 | — | 0.15× | ||
| Q3 24 | — | 0.15× | ||
| Q2 24 | — | 0.16× | ||
| Q1 24 | 0.35× | 0.16× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $9.4M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $8.1M |
| 自由现金流率自由现金流/营收 | -7.1% | 6.3% |
| 资本支出强度资本支出/营收 | 0.1% | 0.9% |
| 现金转化率经营现金流/净利润 | — | 4.76× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $33.4M |
8季度趋势，按日历期对齐
| Q4 25 | $-14.2M | $9.4M | ||
| Q3 25 | $108.5M | $10.2M | ||
| Q2 25 | $4.4M | $4.3M | ||
| Q1 25 | $-53.4M | $12.0M | ||
| Q4 24 | $19.4M | $11.9M | ||
| Q3 24 | $34.1M | $6.8M | ||
| Q2 24 | $-8.3M | $3.1M | ||
| Q1 24 | $-133.0M | $2.5M |
| Q4 25 | $-14.3M | $8.1M | ||
| Q3 25 | $108.3M | $10.1M | ||
| Q2 25 | $4.4M | $4.2M | ||
| Q1 25 | $-53.4M | $11.0M | ||
| Q4 24 | $19.3M | $11.7M | ||
| Q3 24 | — | $6.6M | ||
| Q2 24 | $-8.4M | $2.7M | ||
| Q1 24 | $-133.3M | $2.3M |
| Q4 25 | -7.1% | 6.3% | ||
| Q3 25 | 23.6% | 8.0% | ||
| Q2 25 | 2.5% | 3.4% | ||
| Q1 25 | -32.0% | 9.7% | ||
| Q4 24 | 9.1% | 10.4% | ||
| Q3 24 | — | 5.8% | ||
| Q2 24 | -4.2% | 2.6% | ||
| Q1 24 | -77.3% | 2.4% |
| Q4 25 | 0.1% | 0.9% | ||
| Q3 25 | 0.0% | 0.0% | ||
| Q2 25 | 0.0% | 0.1% | ||
| Q1 25 | 0.0% | 0.9% | ||
| Q4 24 | 0.0% | 0.2% | ||
| Q3 24 | 0.0% | 0.2% | ||
| Q2 24 | 0.0% | 0.3% | ||
| Q1 24 | 0.2% | 0.3% |
| Q4 25 | — | 4.76× | ||
| Q3 25 | 0.50× | 1.54× | ||
| Q2 25 | — | 0.71× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 2.02× | ||
| Q3 24 | — | 8.81× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
BWMN
暂无分部数据
